4 New Ways to Play the Ageing Demographic Theme

One name might be down, but several options remain to play this dominant demographic trend.

| More on:
The Motley Fool

This week’s news of the Loblaw takeover of Shoppers Drug Mart (TSX:SC) has implications for Canadian investors on a number of levels.  You can get more on our takeover thoughts by checking out this recent Fool.ca post or this week’s edition of Take Stock.

One of the big repercussions for Canadian investors is that the whole thesis behind investing in Shoppers Drug Mart has changed.  This had been one of Canada’s great ways to play the dominant demographic theme of our day – the baby boom.  Simply, as this demographic ages, they’re going to need more health related products.  There is no Canadian entity better suited to supplying these products than Shoppers.  Loblaw clearly understands this.

Canadian investors looking for a pure-play on the ageing demographic must now change their tune.

Here are 4 ways that you can deploy your Shoppers’ proceeds and continue on with a similar exposure:

Walgreen’s (NYSE:WAG) – Why not do a little cross border shopping?  You can very easily hop from Canada’s leading drug store chain into the leading drug retailing chain south of the border.  With its $71 billion in annual revenues, Walgreen’s dwarfs Shoppers’ mere $11 billion or so and with an EV/EBITDA multiple of 10.6, the two trade at a similar valuation.

If however, you’d like to keep your money in the Canadian market, here are some other options….

Jean Coutu (TSX:PJC.A) – The Quebec based pharmacy has always been somewhat of an also ran relative to Shoppers in the eye of many market participants.  However, with Shoppers set to fade from the public markets, Canadian pharmacy investors now have but one place to turn.  The company recently offloaded a nearly $200 million stake in U.S. pharmacy Rite-Aid, a position that has been somewhat of an albatross over the years.  The stock however has responded to the lancing of Rite-Aid, as well as the Shoppers transaction, as it has climbed by more than 30% thus far in 2013 and trades with an EV/EBITDA multiple of 12.4, eclipsing both Shoppers and Walgreen’s current valuations.

Extendicare (TSX:EXE) and Chartwell Retirement Residences (TSX:CSH.UN) – moving away from the pharmaceutical theme, two other names that should benefit from an ageing demographic operate in the realm of seniors housing and care.  Both of these names appear to be playing in the right sandbox, and pay seemingly attractive yields of 7.1% for Extendicare and 5.3% for Chartwell, but you’ll want to do your homework on each before jumping in.  Over the past 5 years or so, though both have performed quite well in dividend adjusted terms, the road hasn’t exactly been a smooth one for shareholders in either company.

The Foolish Bottom Line

Over the long-term, investing in the baby-boomers has been a good way to make a lot of money.  It’s very clear where this population bubble is headed, and getting positioned a tad early could result in big rewards for investors.  For Canadian investors, even though Shoppers is about to disappear, other options still exist.

Shoppers was one of the 5 stocks suggested in our special FREE report “5 Stocks to Replace Your Canadian Index Fund”.  To download this report and learn about the remaining 4, simply click here now.

The Motley Fool’s purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool Canada’s free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead.

Follow us on Twitter and Facebook for the latest in Foolish investing.

Fool contributor Iain Butler doesn’t own shares in any of the companies mentioned at this time.  The Motley Fool doesn’t own shares in any of the companies mentioned.   

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

More on Investing

Dividend Stocks

A Dividend Behemoth I’d Buy Over Brookfield Renewable Stock Right Now

Renewable energy stocks look great long term, but not all are set up to produce stable dividends in that time.…

Read more »

woman looks at iPhone
Retirement

Retirees: 3 Income Stocks Every Canadian Needs to Buy Now

Retirees: these are the only three dividend stocks you need to get started in creating passive income during retirement.

Read more »

woman analyze data
Dividend Stocks

1 Magnificent TSX Dividend Stock Down 15% to Buy Now

This top dividend stock is a must buy for long-term holders and short-term dividend seekers.

Read more »

Paper Canadian currency of various denominations
Dividend Stocks

Dividend Powerhouses: 3 Canadian Passive-Income Stocks for Every Portfolio

These stocks are a fantastic way to generate income over time while you sit back and watch your portfolio grow.

Read more »

tsx today
Stock Market

TSX Today: What to Watch for in Stocks on Tuesday, October 8

Overnight declines in commodity prices could pressure the TSX index at the open today as China’s economic stimulus measures and…

Read more »

Tech Stocks

Down Over 20%: Time to Buy These Discounted TSX Stocks?

Given their discounted stock prices and healthy growth prospects, I am bullish on these three TSX stocks.

Read more »

Dog smiles with a big gold necklace
Dividend Stocks

The Smartest Dividend Stocks to Buy With $400 Right Now

Even with just $400, these dividend stocks could help Canadians build a solid income-generating portfolio.

Read more »

Energy Stocks

Where will Enbridge Stock be in 1, 3, and 5 years?

Let's dive into some projections as to where Enbridge (TSX:ENB) could be headed moving forward over the next few years.

Read more »